Federal psychedelics momentum
- The administration issued an executive order urging expedited FDA review of certain psychedelic drugs, with new attention on ibogaine. - HHS/ARPA-H announced up to $139 million through the EVIDENT initiative to validate psychedelic treatments for serious mental illness. - Political acceleration coexists with industry caution about bypassing usual regulatory pathways and inflating patient expectations. (time.com) (x.com) (biospace.com)
President Donald Trump signed an April 18 executive order telling federal agencies to speed the path for some psychedelic drugs, including ibogaine, through Food and Drug Administration review. (whitehouse.gov) The White House said the order lets qualifying psychedelic drugs receive Commissioner’s National Priority Vouchers and tells the Food and Drug Administration and Drug Enforcement Administration to create an access pathway for eligible patients using investigational drugs under review. (whitehouse.gov) The same order directs the Department of Health and Human Services to put $50 million in Advanced Research Projects Agency for Health matching funds behind state psychedelic-research programs for serious mental illness, and to work with the Department of Veterans Affairs and private companies on clinical-trial participation and evidence generation. (whitehouse.gov) Three days later, on April 21, the Advanced Research Projects Agency for Health said the first teams in its EVIDENT initiative could receive up to $139.4 million to build “FDA-ready” measures for rapid-acting behavioral-health treatments, including psychedelics. (hhs.gov) EVIDENT stands for Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health. The agency said it is trying to measure, with clinical and physiological data, which treatments work, for which patients, rather than fund psychedelics alone. (hhs.gov) Ibogaine, the drug getting the most attention in the order, is a psychoactive compound tied to clinics in Mexico that some veterans have sought out for traumatic brain injury, post-traumatic stress disorder, addiction and other conditions. NBC News reported the drug also carries serious safety concerns. (nbcnews.com) The order does not waive the usual evidence standard for approval. TIME reported that experts said the Food and Drug Administration would still need the same safety and efficacy data, even as the White House signaled unusual political support for scheduled substances as medicines. (time.com) That political push landed in a field that has already had setbacks. TIME noted that the Food and Drug Administration rejected an MDMA application for post-traumatic stress disorder two years ago and declined accelerated consideration for Compass Pathways’ synthetic psilocybin treatment late last year. (time.com) Some drugmakers welcomed the move. BioSpace reported Compass Pathways shares jumped 25% in premarket trading on Monday, and company executives said the order could help patients who have not responded to existing mental-health treatments. (biospace.com) Others warned that the White House was pressing too directly on a regulator that is supposed to evaluate drugs independently. BioSpace quoted University of Pennsylvania professor Holly Fernandez Lynch saying it was “pretty extreme” for the White House to direct the Food and Drug Administration on specific products. (biospace.com) For now, Washington has moved psychedelics from a niche research debate into mainstream federal health policy. The next test is whether faster reviews and new research money produce data strong enough for standard Food and Drug Administration approval. (whitehouse.gov)
